Blueprint Medicines Corporation (0HOJ.L)
USD 85.0
(-2.48%)
USD 85.0
(-2.48%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 610.96 Million USD | 184.14% |
| 2022 | 215.02 Million USD | 108.12% |
| 2021 | 103.31 Million USD | 26.5% |
| 2020 | 81.66 Million USD | -8.37% |
| 2019 | 89.12 Million USD | 509.74% |
| 2018 | 14.61 Million USD | -10.5% |
| 2017 | 16.33 Million USD | 384.6% |
| 2016 | 3.37 Million USD | -14.64% |
| 2015 | 3.94 Million USD | -46.2% |
| 2014 | 7.33 Million USD | 240.51% |
| 2013 | 2.15 Million USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q3 | 341.53 Million USD | -37.95% |
| 2024 Q1 | 432.29 Million USD | -29.24% |
| 2024 Q2 | 550.44 Million USD | 27.33% |
| 2023 Q4 | 610.96 Million USD | 627.02% |
| 2023 Q1 | 89.94 Million USD | -58.17% |
| 2023 FY | 610.96 Million USD | 184.14% |
| 2023 Q2 | 87.04 Million USD | -3.21% |
| 2023 Q3 | 84.03 Million USD | -3.46% |
| 2022 FY | 215.02 Million USD | 108.12% |
| 2022 Q4 | 215.02 Million USD | -1.62% |
| 2022 Q3 | 218.55 Million USD | 122.65% |
| 2022 Q2 | 98.16 Million USD | -2.58% |
| 2022 Q1 | 100.76 Million USD | -2.47% |
| 2021 FY | 103.31 Million USD | 26.5% |
| 2021 Q3 | 75.05 Million USD | -2.87% |
| 2021 Q4 | 103.31 Million USD | 37.65% |
| 2021 Q1 | 79.47 Million USD | -2.68% |
| 2021 Q2 | 77.27 Million USD | -2.77% |
| 2020 Q2 | 85.72 Million USD | -2.21% |
| 2020 Q3 | 83.73 Million USD | -2.32% |
| 2020 FY | 81.66 Million USD | -8.37% |
| 2020 Q4 | 81.66 Million USD | -2.47% |
| 2020 Q1 | 87.66 Million USD | -1.64% |
| 2019 Q3 | 90.92 Million USD | -1.86% |
| 2019 Q1 | 94.32 Million USD | 545.29% |
| 2019 Q4 | 89.12 Million USD | -1.97% |
| 2019 Q2 | 92.64 Million USD | -1.78% |
| 2019 FY | 89.12 Million USD | 509.74% |
| 2018 Q1 | 14.18 Million USD | -13.12% |
| 2018 FY | 14.61 Million USD | -10.5% |
| 2018 Q2 | 13.76 Million USD | -3.02% |
| 2018 Q3 | 13.33 Million USD | -3.11% |
| 2018 Q4 | 14.61 Million USD | 9.64% |
| 2017 Q3 | 8.46 Million USD | 128.92% |
| 2017 Q2 | 3.69 Million USD | -1.52% |
| 2017 Q4 | 16.33 Million USD | 92.97% |
| 2017 FY | 16.33 Million USD | 384.6% |
| 2017 Q1 | 3.75 Million USD | 11.39% |
| 2016 Q3 | 5.03 Million USD | -12.53% |
| 2016 FY | 3.37 Million USD | -14.64% |
| 2016 Q4 | 3.37 Million USD | -33.03% |
| 2016 Q2 | 5.75 Million USD | -11.11% |
| 2016 Q1 | 6.47 Million USD | 63.93% |
| 2015 Q1 | 6.52 Million USD | -11.08% |
| 2015 FY | 3.94 Million USD | -46.2% |
| 2015 Q2 | 9.36 Million USD | 43.59% |
| 2015 Q3 | 8.4 Million USD | -10.26% |
| 2015 Q4 | 3.94 Million USD | -53.04% |
| 2014 Q1 | - USD | 0.0% |
| 2014 Q4 | 7.33 Million USD | 0.0% |
| 2014 FY | 7.33 Million USD | 240.51% |
| 2013 FY | 2.15 Million USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| uniQure N.V. | 130.06 Million USD | -369.736% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | -972.089% |
| Amicus Therapeutics, Inc. | 387.85 Million USD | -57.522% |
| Atara Biotherapeutics, Inc. | 45.69 Million USD | -1237.102% |
| bluebird bio, Inc. | 224.41 Million USD | -172.242% |
| Cara Therapeutics, Inc. | 37.07 Million USD | -1547.731% |
| Imunon, Inc. | 1.13 Million USD | -53526.416% |
| Editas Medicine, Inc. | 24.37 Million USD | -2406.819% |
| IQVIA Holdings Inc. | 12.95 Billion USD | 95.284% |
| Mettler-Toledo International Inc. | 1.97 Billion USD | 69.074% |
| Myriad Genetics, Inc. | 130.9 Million USD | -366.739% |
| Neurocrine Biosciences, Inc. | 258.3 Million USD | -136.532% |
| Supernus Pharmaceuticals, Inc. | 33.19 Million USD | -1740.469% |
| Verastem, Inc. | 40.08 Million USD | -1424.128% |
| Walgreens Boots Alliance, Inc. | 8.04 Billion USD | 92.405% |
| Waters Corporation | 2.3 Billion USD | 73.5% |
| Thermo Fisher Scientific Inc. | 31.3 Billion USD | 98.049% |
| Biogen Inc. | 7.18 Billion USD | 91.5% |
| Nektar Therapeutics | 112.62 Million USD | -442.475% |
| Perrigo Company plc | 3.63 Billion USD | 83.182% |
| Dynavax Technologies Corporation | 252.41 Million USD | -142.044% |
| Illumina, Inc. | 1.48 Billion USD | 58.968% |
| Corbus Pharmaceuticals Holdings, Inc. | 3.23 Million USD | -18764.823% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -60996.2% |
| Heron Therapeutics, Inc. | 173.75 Million USD | -251.627% |
| Unity Biotechnology, Inc. | 23.53 Million USD | -2495.531% |
| BioMarin Pharmaceutical Inc. | 593.09 Million USD | -3.013% |
| Sangamo Therapeutics, Inc. | 33.51 Million USD | -1722.951% |
| Evolus, Inc. | 120.35 Million USD | -407.616% |
| Adicet Bio, Inc. | 17.7 Million USD | -3351.178% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | -19775.146% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 77.396% |
| Esperion Therapeutics, Inc. | 501.54 Million USD | -21.816% |
| FibroGen, Inc. | 89.69 Million USD | -581.14% |
| Agilent Technologies, Inc. | 2.73 Billion USD | 77.661% |
| OPKO Health, Inc. | 222.03 Million USD | -175.166% |
| Homology Medicines, Inc. | 43.17 Million USD | -1315.05% |
| Geron Corporation | 35.05 Million USD | -1643.066% |
| Alnylam Pharmaceuticals, Inc. | 2.34 Billion USD | 73.924% |
| Exelixis, Inc. | 189.94 Million USD | -221.654% |
| Viking Therapeutics, Inc. | 936 Thousand USD | -65173.718% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | 96.74 Million USD | -531.505% |
| Zoetis Inc. | 6.56 Billion USD | 90.692% |
| Axsome Therapeutics, Inc. | 178.07 Million USD | -243.102% |
| Abeona Therapeutics Inc. | 4.4 Million USD | -13779.191% |
| Vertex Pharmaceuticals Incorporated | 724.7 Million USD | 15.694% |
| Kala Pharmaceuticals, Inc. | 34.19 Million USD | -1686.961% |
| Ionis Pharmaceuticals, Inc. | 1.4 Billion USD | 56.372% |
| Sarepta Therapeutics, Inc. | 1.13 Billion USD | 46.053% |
| Corcept Therapeutics Incorporated | - USD | -Infinity% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | 59.249% |
| Insmed Incorporated | 1.19 Billion USD | 48.803% |
| TG Therapeutics, Inc. | 100.11 Million USD | -510.242% |
| Incyte Corporation | 29.16 Million USD | -1995.062% |
| Emergent BioSolutions Inc. | 446.5 Million USD | -36.834% |